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6.4 nmol/Land that showed an H243Y
mutant type codon. The role of such a
polymorphism appears unclear. We
found no association between the 3-bp
indel in G7 and in vitro dhART sus-
ceptibility because mutants were regu-
larly distributed in highly susceptible
isolates and in isolates having a dimin-
ished susceptibility.
For our samples obtained during
2004–2006, the geometric mean IC50
value for dhART was very close to
values found in Cameroon during
1997–1998 (mean dhART IC50 = 1.11
nmol/L) (9), in Senegal in 2001 (mean
artemether IC50 = 1.3 nmol/L) (5), and
in Republic of Congo during
2005–2006 (mean dhART IC50 = 1.02
nmol/L) (10). Ringwald et al.
observed a narrower range of IC50s,
but their series included only 65 sam-
ples (9). Previous comparisons
between ACs suggested that dhART is
1.7 times more potent than artemether
against  P. falciparum (9). Thus, the
highest IC50 value for artemether
observed by Jambou et al. in Senegal
(44.7 nmol/L) (5) is comparable to the
highest IC50 value for dhART in our
series (31.8 nmol/L). The resistance
levels of ACs are still undefined. For
artemether, Jambou et al. used a
threshold of 30 nmol/L to evaluate the
association between the S769N muta-
tion and in vitro susceptibility. The
presence of ATPase6 S769N was not
associated with diminished in vitro
susceptibility in our series.
Conversely, the only S769N mutant
that we observed was found in a fully
susceptible isolate. Thus, we con-
firmed that polymorphism exists in
this gene in positions 769 and 243, but
we did not prove an association
between these point mutations and
resistance to ACs. Similarly, our
results did not support the hypothesis
of an association between the 3-bp
indel in G7 and resistance to ACs.
ACs, considered the most impor-
tant class of antimalarial drugs, merit
close surveillance for susceptibility.
Continued monitoring of the efficacy
of their associated partner drugs also
appears to be essential.
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Real-time PCR for
Francisella 
tularensis
Types A and B 
To the Editor: Francisella
tularensis, the etiologic agent of
tularemia, is highly infectious and
considered a potential bioweapon
(1–3). Although 4 subspecies of F.
tularensis are recognized, most cases
of tularemia are due to infection by
subsp. tularensis (type A) or holarcti-
ca (type B). North America is the
only region where both type A and
type B cause human disease.
Subspecies novicida is also found in
North America, but it is of reduced
virulence. Disease incidence attribut-
able to either type A or type B isLETTERS
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essentially unknown because the tra-
ditional method for classification of
these subspecies is glycerol fermenta-
tion, which requires culture recovery
(4).  F. tularensis is fastidious and
slow growing, with isolates recov-
ered in a small percentage of cases.
We developed real-time TaqMan
PCR assays for classification of F.
tularensis type A and type B after F.
tularensis is identified by culture or,
in the absence of culture, by a PCR
method such as the F. tularensis mul-
titarget TaqMan assay (5). The type A
TaqMan assay targets pdpD, which is
present in type A, almost entirely
absent from type B, and contains a
144-bp insert in novicida (6,7) (F: 5′-
GAGACATCAATTAAAAGAAG-
CAATACCTT-3′; R: 5′-CCAAGAG-
TACTATTTCCGGTTGGT-3′; probe:
5′-AAAATTCTGC“T”CAGCA-
GGATTTTGATTTGGTT-3′). The
type B assay targets a junction
between ISFtu2 and a flanking 3′
region (GenBank AY06) (F: 5′-
CTTGTACTTTTATTTGGCTACT-
GAGAAACT-3′; R: 5′- CTTGCTTG-
GTTTGTAAATATAGTGGAA-3′;
probe: 5′- ACCTAGTTCAACC“T”-
CAAGACTTTTAGTAATGGGAAT-
GTCA-3′). In type A and novicida,
ISFtu2 is absent from this position
(8). Oligonucleotides were designed
with Primer Express version 2.0
(Applied Biosystems, Foster City,
CA, USA). Probes were synthesized
with a 5′ 6-carboxy-fluorescein
reporter and an internal quencher
(either BHQ1 [type A] or QSY-7 [type
B]) at the nucleotide position indicat-
ed by the quotation marks.
Assays were optimized by using 1
ng of type A(strain SchuS4) or type B
(strain LVS) DNA on the LightCycler
1.2 (Roche Applied Science,
Indianapolis, IN, USA). Optimized
concentrations (20 µL final volume)
were 1× LightCycler Fast Start DNA
Master Hybridization Probe mix
(Roche), 750 nmol/L primers, 200
nmol/L probe, 5 mmol/L MgCl2 and
0.5 U uracil-DNA glycosylase. PCR
conditions were 50°C for 2 min, 95°C
for 10 min, 45 cycles of 95°C for 10 s,
and 65°C for 30 s, then 45°C for 5
min. Cycle threshold (Ct) values were
calculated by using the second deriva-
tive maximum method with the y-axis
at F1/F3 (LightCycler software ver-
sion 3.5).
Sensitivity of each assay was
assessed by using 10-fold serial dilu-
tions (100,000 to 1 genomic equiva-
lents [GE]) of SchuS4 or LVS DNA.
Testing was performed in triplicate,
with a reproducible detection limit of
10 GE for both assays. Specificity of
each assay was tested with 1 ng of
DNA from a panel of 62 Francisella
isolates (online Appendix Table,
available from http://www.cdc.gov/
ncidod/EID/vol12no11/06-0629_
appT.htm) and 22 non-Francisella
isolates (Acinetobacter, Bacillus,
Brucella, Corynebacterium, Entero-
bacter, Enterococcus, Escherichia,
Haemophilus, Klebsiella, Legionella,
Proteus, Pseudomonas, Serratia,
Staphylococcus, Streptococcus, and
Yersinia species). Isolates were
grown, DNA purified, and quantified
as previously described (5). Specifi-
city was also evaluated with DNA (2
µL) extracted as previously described
from  Francisella-like tick endosym-
bionts of Dermacentor variabilis and
Francisella-like soil bacteria (online
Appendix) (9,10). The type A assay
recognized all type A isolates with an
average Ct value of 17.9 (n = 19). The
type B assay detected all type B
strains with an average Ct value of
17.1 (n = 21). Neither assay displayed
cross-reactivity with F. tularensis
subsp. novicida (n = 7), F. philomira-
gia (n = 15), Francisella-like tick
endosymbionts (n = 3), Francisella-
like soil bacteria (n = 7) (Appendix),
or non-Francisella spp. (n = 22).
To evaluate the ability of the type
A and type B TaqMan assays, in con-
junction with the multitarget assay, to
identify F. tularensis and classify sub-
species in primary specimens, human,
animal, and tick samples were tested
(Table) available from DNA was
extracted from 200 µL fluid, 25 mg
liver, and 10 mg spleen or lung by
using the QIAamp DNA MiniKit
(Qiagen, Valencia, CA, USA) and 1
µLtested. Multitarget PCR conditions
were as described (5).
The multitarget and subspecies-
specific PCR assays accurately identi-
fied and classified F. tularensis in all
specimens positive by standard diag-
nostic methods (Table). In addition,
the type Aand type B assays provided
subspecies information for positive
specimens in which an isolate was not
recovered for glycerol fermentation
testing (Table). All specimens nega-
tive by standard diagnostic methods
tested negative by PCR. These pre-
liminary results suggest that a F.
tularensis PCR identification method,
in combination with the type A and
type B assays, provides the capability
to identify F. tularensis and determine
subspecies in the absence of culture.
We describe real-time PCR assays
capable of classifying F. tularensis
type A and type B and distinguishing
these subspecies from the less virulent
subsp.  novicida. These assays are
designed for use after F. tularensis has
been identified by culture or by PCR.
Supplemental use of these assays will
allow laboratories to actively subtype
F. tularensis isolates and primary
specimens, thus providing subspecies
information for a higher percentage of
tularemia cases. Improved subspecies
information will further understand-
ing of the disease incidence and geo-
graphic distribution of F. tularensis
type A and type B in North America.
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